Business
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN QUEBEC AND NOVA SCOTIA
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN QUEBEC AND NOVA SCOTIA.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN QUEBEC AND NOVA SCOTIA\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN QUEBEC AND NOVA SCOTIA\nCanada NewsWire\nMONTREAL, Dec. 15, 2021\n\n\n\nPublic reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population. More than 90% private insurance coverage across Canada MONTREAL, Dec. 15, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, is proud to announce a major milestone for its two innovative Asthma therapies ; Atectura Breezhaler and Enerzair Breezehaler are now reimbursed by the Quebec RAMQ, and by Nova Scotia Minister of Health, effective December 15, 2021 and December 2, 2021 respectively. The listings now appear on the Quebec List of Medications and the Nova Scotia Drug Formulary. \n\n \n \n \n \n \n \n\n \n\"We are pleased to be reporting today the addition of Quebec and Nova Scotia to join Alberta on the list of provincial public coverage secured for both asthma medications\", said Frederic Fasano, Valeo's President and Chief Operating Officer. \"Public Reimbursment access makes a meaningful impact for asthma patients left with no coverage so far, and also simplify health care providers procedures to provide access of both medications to their patients. Enerzair and Atectura are innovative asthma therapies that are helping make asthma control a more attainable goal for Canadians asthma patients\".  \nPublic coverage in these jurisdictions also means that private payers mimiking the public plans will now cover both drugs. Therefore Enerzair and Atectura are now covered for more than 90% of privately covered lives accross Canada. \nBoard of Directors Change\nThe Company also announced today the retirement of Mr. Michael G. Wells as a member of the Board of Directors of the Co...